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as determined by molecular technology, have signiﬁcant pre-
dictive value for transplant related morbidity and mortality
(TMM) and thus transplant outcome. Thus, a computer search
often identiﬁes only potential serological matches with further
molecular typing needed to determine whether the serologic
“6 of 6” match is a molecular “10 of 10 match” or less. The
requisition, transportation and molecular typing procedure of
donor samples are time consuming (2-4 weeks). Added to the
2-4 weeks of clearing, scheduling and preparing the donor
for hematopoietic stem cell harvest, the median time from
start of the formal search to infusion of the unrelated stem
cells currently is 50-60 days in the U.S., only able to be
further shortened if and when more donors are listed in the
MUD registries with their complete molecular class I and II
typing, and or if able to use one or more unrelated umbilical
cord bloods (UCB) as the stem cell source. In the U.S.,
efforts are being made in collaboration with European UCB
programs to not only generate large UCB banks, but to assure
that the UCB stored is of maximum cellularity and quality.
The potential of receiving appropriate hematopoietic stem
cells in the form of UCB within 2 weeks of a request, has
resulted in a signiﬁcant rise of UCB transplants in adults in
the U.S., with preliminary results being encouraging, but with
the number of adult patients treated, combined with a short
follow-up, making it difﬁcult to declare this as a “standard of
care” hematopoietic stem cell source for adult patients today,
for which reasons most of such transplants are (and should
be) done on investigational protocols.
The discrepancy in risk of TMM and mortality between pa-
tients with MyMal undergoing an alloSCT using an unrelated
or related stem cell source was signiﬁcant in disfavor of
MUD alloSCT up to 10 years ago, but has greatly decreased
in the last 10 years, especially if comparing 10/10 matched
unrelated stem cell sources to HLA-identical sibling stem
cell sources, regardless of the age of the patients. For older
patients undergoing NST or RIC transplants, some data even
suggests that MUD derived alloSCT’s carry a beneﬁt over
family matched, mainly in reducing the risk of post-transplant
relapse of the original MyMal, but also with no, or only
minimal increase in the risk of TMM. However more data
and longer follow-up is needed before any ﬁrm conclusions
can be made as to the relative merits or current differences
of using MUD derived hematopoietic stem cells vs. matched
related stem cells.
Conclusion
Improvements in identifying patients with MyMal who most
likely will beneﬁt from an alloSCT and those who most
likely will not, combined with the ability to administrate a
graft-versus MDS/AML effect in the (older) group of patients
with the highest incidence of these diseases, has set the stage
for a more appropriate use of alloSCT in patients with these
diseases, perhaps even laying the ground for a consensus as
to what patients with MyMal should be transplanted and what
patients should not, a consensus that currently does not exist.
Improvement in molecularly matching unrelated donors to
patients, and the development of more safely using UCB
transplants in adults, may result in more patients with MyMal
in need of an alloSCT undergoing this procedure, a devel-
opment strongly needed as in 2006, approximately 80% of
patients dependent on identifying an unrelated donor source
were unable to proceed to an alloSCT in the U.S.
Today, only a select, heterogeneous group of patients with
MyMal is undergoing alloSCT of any type, including from
MUD’s. This in combination with improvements rendered
from using new potent medications in patients with especially
MDS, makes for an ongoing controversy as to which pa-
tients with MyMal should proceed to an alloSCT. However,
further improvements in the diagnosis, risk allocation and
non-transplant treatment of patients with these diseases may
diminish this controversy.
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Allogeneic stem cell transplantation (allo-SCT) has been
routinely performed as postremission therapy for ALL. But
still compared to standard maintenance chemotherapy or
autologous stem cell transplantation the role of allo-SCT is
unclear. In high risk ALL patients allo-SCT has the advantage
compared to other treatment options [1], but for standard risk
patients this was not proved [2]. In the EORTC ALL-4 trial
the postremission treatment outcome was analyzed according
to donor versus no donor comparison.
Patients and Methods
In the ALL-4 trial for induction therapy patients were ran-
domized either to receive prednisolone or dexamethasone
together with standard chemotherapy. Patients younger than
50 years of age with a family donor who achieved CR
with induction therapy and/or consolidation were assigned to
undergo allo-SCT whereas patients without the donor were
planned to be autografted or treated with chemotherapy.
Results
A total of 325 patients entered the trial. The median
age was 32 years (range 15-72), M/F 187/138. ALL/NHL
313/12, B-ALL/T-ALL 217/90, mediastinal mass 11,4%,
WBC <30×109/L 67%, CNS involvement 21%. Among 212
patients < 50 yrs, 189 (85.2%) reached CR; 198 patients were
HLA typed; 90 had a donor and 108 had no sibling donor. The
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Table 1. Patients < 50 yrs in CR1 assigned to be allografted according
sibling donor availability
EFS/Survival status Outcome of patients < 50 years who achieved CR1 (%)
(%) at 5 years
All Prednisolone Deaxamethasone
patients group group
No donor Donor No donor Donor No donor Donor
CCR 36 39 34 43 39 36
Relapse 58 38 63 35 57 40
TRM 5 23 3 21 4 26
DFS 36 41 33 46 37 38
Overall survival 38 42 37 55 38 39
ﬁve-year DFS was similar for patients with or without donor
(41% for donor group vs. 36% for no donor group, p=0, 38,
Table 1).The relapse incidence was signiﬁcantly lower (38%
vs. 58% p<0.05, Table 1), and TRM was signiﬁcantly higher
(22% vs. 3%, p <0.05, Table 1) for patients with a donor.
Patients with a donor randomized to receive prednisone in
induction therapy showed a trend for a lower TRM and sim-
ilar antileukemic efﬁcacy compared to dexamethasone group
Figure 1. Survival from CR for patients with a donor randomized to
receive prednisone (R-PDN) or dexamethazone (R-DXM)
Figure 2. Survival from CR for patients receiving prednisone according to
donor availability
(Table 1).The patients with a donor received prednisone in
induction therapy have the advantage of survival compared to
patients without the donor (55% vs.39% at 5 years, Fig. 1).
The better survival was also observed for the patients with a
donor receiving prednisone compared to patients with a donor
receiving dexamethasone (55% vs. 39% at 5 years, Fig. 2).
Conclusions
Analysis by intention to treat of the EORTC ALL-4 trial
reveals that the policy to perform an allo-SCT in case of
sibling donor is available does not result in a signiﬁcantly
better outcome than to offer auto-SCT or maintenance ther-
apy. The lower relapse incidence in patients with a donor was
annulled by a higher TRM. Patients with a donor receiving
prednisolone for induction therapy have the advantage in
survival. This data speaks in favor that less intensive im-
munosuppressive regimen before transplant might decrease
transplant toxicity and thus with the similar antileukemic
efﬁcacy might improve the treatment outcome.
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Introduction
Imatinib therapy produces complete cytogenetic responses in
70% to 85% of patients with CML in early chronic phase.
With a median follow up of 5 years, the annual rate of
resistance/progression is 4% and of mortality 1-2% [1]. The
estimated 5-year survival rate is about 90% [1,2]. Resistance
to imatinib, in 30% to 50% of resistant cases, is through
point mutations of the BCR-ABL kinase domain. Over 40
different mutations have been reported which can produce
absolute (e.g. T315I), relative, or no resistance to tyrosine
kinase inhibitors (TKIs) [2]. The degree of resistance depends
on the mutation location and its selective effect to speciﬁc
TKIs [3–6]. Other mechanisms of resistance include BCR-
ABL-dependent (e.g., overexpression and ampliﬁcation) and
BCR-ABL- independent mechanisms (e.g., overexpression
of Src-related kinases) [4]. New-generation TKIs, or non-
TKI agents may overcome or prevent the development of
resistance. These are discussed below.
Dasatinib (Sprysel; BMS-354825)
Dasatinib is an ATP-competitive, dual-speciﬁc Src- and
Abl-kinase inhibitor. Src activation may play a role in the
